Assertio (ASRT) Stock Forecast, Price Target & Predictions
ASRT Stock Forecast
Assertio stock forecast is as follows: an average price target of $2.88 (represents a 136.07% upside from ASRT’s last price of $1.22) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ASRT Price Target
The average price target for Assertio (ASRT) is $2.88 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $2.75. This represents a potential 136.07% upside from ASRT's last price of $1.22.
ASRT Analyst Ratings
According to 2 Wall Street analysts, Assertio's rating consensus is 'Buy'. The analyst rating breakdown for ASRT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Assertio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | Naz Rahman | Maxim Group | $3.00 | $1.47 | 104.08% | 145.90% |
| May 28, 2024 | Scott Henry | Industrial Alliance Securities | $2.75 | $1.00 | 175.00% | 125.41% |
The latest Assertio stock forecast, released on Jul 26, 2024 by Naz Rahman from Maxim Group, set a price target of $3.00, which represents a 104.08% increase from the stock price at the time of the forecast ($1.47), and a 145.90% increase from ASRT last price ($1.22).
Assertio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $3.00 | $2.88 |
| Last Closing Price | $1.22 | $1.22 | $1.22 |
| Upside/Downside | -100.00% | 145.90% | 136.07% |
In the current month, the average price target of Assertio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Assertio's last price of $1.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 03, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 28, 2024 | Alliance Global Partners | - | Buy | Initialise |
Assertio's last stock rating was published by H.C. Wainwright on Jul 03, 2024. The company Initialise its ASRT rating from "null" to "Buy".
Assertio Financial Forecast
Assertio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $35.63M | $40.99M | $42.47M | $50.35M | $34.21M | $35.13M | $36.54M | $33.33M | $25.47M | $25.37M | $26.84M | $30.18M | $34.56M | $20.62M | $20.92M | $59.23M | $55.15M |
| Avg Forecast | $29.00M | $29.20M | $29.41M | $29.62M | $34.12M | $32.88M | $31.80M | $30.99M | $29.30M | $28.87M | $30.08M | $29.30M | $33.60M | $50.17M | $39.83M | $37.64M | $47.33M | $31.36M | $31.78M | $32.66M | $30.38M | $21.64M | $19.98M | $23.98M | $27.30M | $32.35M | $25.17M | $10.95M | $25.01M | $50.57M |
| High Forecast | $30.53M | $30.74M | $30.96M | $31.18M | $35.91M | $34.61M | $33.47M | $32.62M | $30.84M | $29.22M | $31.67M | $30.84M | $35.37M | $52.81M | $41.93M | $39.62M | $49.82M | $33.01M | $32.81M | $33.72M | $31.36M | $22.34M | $20.63M | $24.75M | $28.18M | $33.40M | $25.99M | $11.30M | $25.82M | $52.21M |
| Low Forecast | $27.60M | $27.80M | $28.00M | $28.20M | $32.47M | $31.30M | $30.27M | $29.50M | $27.89M | $28.51M | $28.63M | $27.89M | $31.98M | $47.75M | $37.92M | $35.82M | $45.05M | $29.85M | $30.82M | $31.68M | $29.46M | $20.99M | $19.38M | $23.26M | $26.48M | $31.38M | $24.41M | $10.62M | $24.25M | $49.05M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.71% | 1.03% | 1.13% | 1.06% | 1.09% | 1.11% | 1.12% | 1.10% | 1.18% | 1.27% | 1.12% | 1.11% | 1.07% | 0.82% | 1.91% | 2.37% | 1.09% |
Assertio's average Quarter revenue forecast for Dec 23 based on 1 analysts is $33.60M, with a low forecast of $31.98M, and a high forecast of $35.37M. ASRT's average Quarter revenue forecast represents a -5.69% decrease compared to the company's last Quarter revenue of $35.63M (Sep 23).
Assertio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-228.27M | $19.80M | $21.10M | $29.90M | $18.38M | $19.96M | $22.45M | $14.86M | $13.69M | $-4.39M | $14.59M | $-25.85M | $-273.00K | $-37.12M | $60.02M | $-158.70M | $41.21M |
| Avg Forecast | $8.76M | $8.83M | $8.89M | $8.95M | $10.31M | $9.94M | $9.61M | $9.37M | $8.85M | $8.72M | $9.09M | $26.23M | $10.15M | $15.16M | $12.04M | $20.73M | $14.30M | $9.48M | $9.60M | $16.39M | $9.18M | $6.54M | $6.04M | $16.05M | $8.25M | $9.78M | $7.61M | $3.31M | $7.56M | $15.28M |
| High Forecast | $9.23M | $9.29M | $9.36M | $9.42M | $10.85M | $10.46M | $10.12M | $9.86M | $9.32M | $8.83M | $9.57M | $31.47M | $10.69M | $15.96M | $12.67M | $24.88M | $15.06M | $9.98M | $9.91M | $19.67M | $9.48M | $6.75M | $6.23M | $19.26M | $8.52M | $10.09M | $7.85M | $3.42M | $7.80M | $15.78M |
| Low Forecast | $8.34M | $8.40M | $8.46M | $8.52M | $9.81M | $9.46M | $9.15M | $8.92M | $8.43M | $8.62M | $8.65M | $20.98M | $9.67M | $14.43M | $11.46M | $16.59M | $13.61M | $9.02M | $9.32M | $13.11M | $8.90M | $6.34M | $5.86M | $12.84M | $8.00M | $9.48M | $7.38M | $3.21M | $7.33M | $14.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.06% | 1.64% | 1.02% | 2.09% | 1.94% | 2.08% | 1.37% | 1.62% | 2.09% | -0.73% | 0.91% | -3.13% | -0.03% | -4.88% | 18.14% | -21.00% | 2.70% |
0 analysts predict ASRT's average Quarter EBITDA for Sep 23 to be $15.16M, with a high of $15.96M and a low of $14.43M. This is -23.43% lower than Assertio's previous annual EBITDA (Jun 23) of $19.80M.
Assertio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-279.54M | $8.47M | $-3.48M | $88.55M | $4.17M | $7.83M | $9.06M | $4.61M | $3.74M | $-14.17M | $4.54M | $-24.35M | $-10.52M | $-34.50M | $41.23M | $-192.63M | $3.33M |
| Avg Forecast | $6.67M | $4.76M | $3.81M | $3.81M | $952.40K | $952.40K | $-317.43K | $-1.27M | $-3.81M | $-3.81M | $-3.05M | $11.43M | $-1.90M | $9.05M | $17.68M | $9.03M | $54.48M | $17.02M | $9.52M | $7.14M | $7.62M | $11.43M | $11.43M | $5.00M | $-13.33M | $-11.43M | $-32.38M | $120.60M | $53.33M | $92.70M |
| High Forecast | $7.12M | $5.09M | $4.07M | $4.07M | $1.02M | $1.02M | $-297.56K | $-1.19M | $-3.57M | $-2.86M | $-2.86M | $13.71M | $-1.79M | $9.67M | $18.89M | $10.84M | $58.21M | $20.42M | $9.92M | $8.57M | $7.94M | $11.91M | $11.91M | $6.00M | $-12.81M | $-10.98M | $-31.11M | $144.72M | $55.58M | $96.60M |
| Low Forecast | $6.25M | $4.46M | $3.57M | $3.57M | $892.79K | $892.79K | $-339.16K | $-1.36M | $-4.07M | $-4.76M | $-3.26M | $9.14M | $-2.04M | $8.48M | $16.58M | $7.23M | $51.07M | $13.61M | $9.15M | $5.71M | $7.32M | $10.98M | $10.98M | $4.00M | $-13.89M | $-11.91M | $-33.74M | $96.48M | $51.25M | $89.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.90% | 0.48% | -0.39% | 1.63% | 0.25% | 0.82% | 1.27% | 0.60% | 0.33% | -1.24% | 0.91% | 1.83% | 0.92% | 1.07% | 0.34% | -3.61% | 0.04% |
Assertio's average Quarter net income forecast for Sep 23 is $9.05M, with a range of $8.48M to $9.67M. ASRT's average Quarter net income forecast represents a 6.82% increase compared to the company's last Quarter net income of $8.47M (Jun 23).
Assertio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $21.00M | $16.77M | $16.90M | $13.71M | $11.90M | $10.54M | $10.64M | $13.28M | $9.31M | $26.23M | $7.73M | $23.13M | $25.75M | $28.13M | $27.31M | $22.95M | $36.12M |
| Avg Forecast | $15.77M | $15.88M | $15.99M | $16.11M | $18.55M | $17.88M | $17.29M | $16.85M | $15.93M | $15.70M | $16.36M | $13.41M | $18.27M | $27.28M | $21.66M | $10.60M | $25.74M | $17.05M | $17.28M | $8.38M | $16.52M | $11.77M | $10.87M | $8.50M | $14.84M | $17.59M | $13.69M | $5.95M | $13.60M | $27.50M |
| High Forecast | $16.60M | $16.72M | $16.84M | $16.96M | $19.53M | $18.82M | $18.20M | $17.74M | $16.77M | $15.89M | $17.22M | $16.09M | $19.23M | $28.72M | $22.80M | $12.72M | $27.09M | $17.95M | $17.84M | $10.06M | $17.05M | $12.15M | $11.22M | $10.20M | $15.32M | $18.16M | $14.13M | $6.15M | $14.04M | $28.39M |
| Low Forecast | $15.01M | $15.12M | $15.22M | $15.33M | $17.66M | $17.02M | $16.46M | $16.04M | $15.16M | $15.51M | $15.57M | $10.73M | $17.39M | $25.97M | $20.62M | $8.48M | $24.50M | $16.23M | $16.76M | $6.71M | $16.02M | $11.41M | $10.54M | $6.80M | $14.40M | $17.06M | $13.28M | $5.77M | $13.19M | $26.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.77% | 1.59% | 0.53% | 0.70% | 0.61% | 1.27% | 0.80% | 0.79% | 2.41% | 0.91% | 1.56% | 1.46% | 2.06% | 4.59% | 1.69% | 1.31% |
Assertio's average Quarter SG&A projection for Dec 23 is $18.27M, based on 1 Wall Street analysts, with a range of $17.39M to $19.23M. The forecast indicates a -13.02% fall compared to ASRT last annual SG&A of $21.00M (Sep 23).
Assertio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.42 | $0.15 | $-0.07 | $1.83 | $0.09 | $0.17 | $0.20 | $0.10 | $0.08 | $-0.32 | $0.12 | $-0.80 | $-0.36 | $-1.40 | $2.32 | $-10.60 | $0.20 |
| Avg Forecast | $0.07 | $0.05 | $0.04 | $0.04 | $0.01 | $0.01 | $-0.00 | $-0.01 | $-0.04 | $-0.04 | $-0.03 | $-0.01 | $-0.02 | $0.10 | $0.19 | $0.18 | $0.57 | $0.07 | $0.10 | $0.08 | $0.08 | $0.12 | $0.12 | $0.08 | $-0.14 | $-0.12 | $-0.34 | $-0.32 | $0.56 | $0.97 |
| High Forecast | $0.07 | $0.05 | $0.04 | $0.04 | $0.01 | $0.01 | $-0.00 | $-0.01 | $-0.04 | $-0.03 | $-0.03 | $-0.01 | $-0.02 | $0.10 | $0.20 | $0.19 | $0.61 | $0.08 | $0.10 | $0.08 | $0.08 | $0.13 | $0.13 | $0.08 | $-0.13 | $-0.12 | $-0.33 | $-0.31 | $0.58 | $1.01 |
| Low Forecast | $0.07 | $0.05 | $0.04 | $0.04 | $0.01 | $0.01 | $-0.00 | $-0.01 | $-0.04 | $-0.05 | $-0.03 | $-0.01 | $-0.02 | $0.09 | $0.17 | $0.17 | $0.54 | $0.07 | $0.10 | $0.08 | $0.08 | $0.12 | $0.12 | $0.08 | $-0.15 | $-0.13 | $-0.35 | $-0.33 | $0.54 | $0.94 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -36.00% | 0.81% | -0.38% | 3.20% | 1.28% | 1.70% | 2.50% | 1.25% | 0.67% | -2.67% | 1.50% | 5.71% | 3.00% | 4.12% | -7.25% | -18.93% | 0.21% |
According to 0 Wall Street analysts, Assertio's projected average Quarter EPS for Sep 23 is $0.10, with a low estimate of $0.09 and a high estimate of $0.10. This represents a -36.67% decrease compared to ASRT previous annual EPS of $0.15 (Jun 23).
Assertio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $1.91 | $16.00 | 737.70% | Buy |
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| ASRT | Assertio | $1.22 | $2.88 | 136.07% | Buy |
| LFCR | Lifecore Biomedical | $5.18 | $8.00 | 54.44% | Buy |
| ALVO | Alvotech | $10.81 | $16.00 | 48.01% | Hold |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| EOLS | Evolus | $17.49 | $22.50 | 28.64% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| CTLT | Catalent | $59.62 | $74.30 | 24.62% | Hold |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| AMRX | Amneal Pharmaceuticals | $8.62 | $7.00 | -18.79% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
ASRT Forecast FAQ
Is Assertio a good buy?
Yes, according to 2 Wall Street analysts, Assertio (ASRT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ASRT's total ratings.
What is ASRT's price target?
Assertio (ASRT) average price target is $2.88 with a range of $2.75 to $3, implying a 136.07% from its last price of $1.22. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Assertio stock go up soon?
According to Wall Street analysts' prediction for ASRT stock, the company can go up by 136.07% (from the last price of $1.22 to the average price target of $2.88), up by 145.90% based on the highest stock price target, and up by 125.41% based on the lowest stock price target.
Can Assertio stock reach $2?
ASRT's average twelve months analyst stock price target of $2.88 supports the claim that Assertio can reach $2 in the near future.
What are Assertio's analysts' financial forecasts?
Assertio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $129.79M (high $136.63M, low $123.54M), average EBITDA is $39.22M (high $41.29M, low $37.34M), average net income is $317.53K (high $547.25K, low $89.67K), average SG&A $70.58M (high $74.29M, low $67.18M), and average EPS is $0.00333 (high $0.00575, low $0.000941). ASRT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $117.24M (high $123.41M, low $111.59M), average EBITDA is $35.43M (high $37.3M, low $33.72M), average net income is $19.05M (high $20.35M, low $17.86M), average SG&A $63.75M (high $67.11M, low $60.68M), and average EPS is $0.2 (high $0.214, low $0.187).
Did the ASRT's actual financial results beat the analysts' financial forecasts?
Based on Assertio's last annual report (Dec 2022), the company's revenue was $156.23M, beating the average analysts forecast of $143.13M by 9.16%. Apple's EBITDA was $91.21M, beating the average prediction of $49.77M by 83.25%. The company's net income was $109.62M, beating the average estimation of $88.16M by 24.35%. Apple's SG&A was $46.79M, missing the average forecast of $68.45M by -31.65%. Lastly, the company's EPS was $2.33, beating the average prediction of $0.822 by 183.34%. In terms of the last quarterly report (Sep 2023), Assertio's revenue was $35.63M, missing the average analysts' forecast of $50.17M by -28.99%. The company's EBITDA was $-228M, missing the average prediction of $15.16M by -1605.57%. Assertio's net income was $-280M, missing the average estimation of $9.05M by -3189.64%. The company's SG&A was $21M, missing the average forecast of $27.28M by -23.01%. Lastly, the company's EPS was $-3.42, missing the average prediction of $0.095 by -3700.00%